This report presents three-year results for zanubrutinib plus venetoclax in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with high-risk genetic features. This investigational combination led to high rates of deep remission and durable responses, regardless of genetic risk factors. Most patients remained progression-free, and the safety profile was reported as manageable. The most common grade ≥3 adverse events (AEs) were decreased neutrophil count, hypertension, and diarrhea. These findings may support the use of this regimen for newly diagnosed CLL/SLL, including those with high-risk features.

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.